The global peptide therapeutics market is witnessing significant growth owing to the rising prevalence of metabolic disorders and chronic conditions such as cancer, diabetes, and cardiovascular diseases. Peptide therapeutics play a vital role in modulating biological activities inside cells and tissues, regulating various metabolic functions. They demonstrate high specificity and affinity for their target receptors and cause fewer undesirable off-target consequences. The advantages of peptides over small molecule drugs include improved solubility, lower toxicity, and better tolerability. With advancements in peptide engineering technologies such as immunization, rational design, and protein expression and purification techniques facilitating the production of novel bioactive peptides, there has been a significant increase in peptide drug development activities globally.
The Global peptide therapeutics market is estimated to be valued at US$ 51133.71 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the peptide therapeutics market are IBM Corporation, SAP SE, Oracle Corporation, ABB Ltd., Infor, Inc., Ultimo Software Solutions BV, CARL International SA, eMaint Enterprises, LLC, Mainsaver, Inc., MEX Pty Ltd., Asset Works LLC, and CGI, Inc. These players are focusing on developing novel peptide-based drugs for chronic metabolic conditions through collaborative research partnerships.
The global Peptide Therapeutics Market Trends provides lucrative growth opportunities for manufacturers in developing therapeutic peptides for rare and orphan indications owing to lack of competing drug therapies. Technological advancements in biologics development such as epitope mapping, rational designing, and expression systems have enabled efficient engineering of novel peptides.
Advancements in peptide synthesis, formulation, and delivery technologies such as long-acting injectables, transdermal, and oral formulations are further driving the adoption of peptide drugs and expanding their applications.
Market Drivers
The increasing demand for more effective and safer drugs with lesser side effects compared to small molecule-based medications is a key factor driving the growth of the global peptide therapeutics market. Peptides demonstrate improved specificity, prolonged duration of action and better pharmacokinetic properties compared to small molecule drugs. Several new peptide drugs in the pipeline for oncology, metabolic disorders, and other therapeutic areas also indicate robust market growth over the forecast period.
Current challenges in Peptide Therapeutics Market:
Peptide therapeutics market faces major challenges which hinders the growth of this market. Huge R&D costs involved in Peptide Therapeutics Market Challenges and Opportunities drug discovery and development act as a major barrier. Designing and synthesizing peptide therapeutics requires extensive research and testing which increases the overall costs. Another challenge is the short half-life of peptide drugs in the body which requires frequent administration. Improving drug stability and extending peptide half-life remain a major challenge. Ensuring production scalability and cost-effective manufacturing are also major hurdles, especially for large volume biologics. Clinical failure and regulatory issues also delay market entry and commercialization of new peptide drugs.
SWOT Analysis
Strength: Peptides offer high selectivity and specificity for molecular targets. They can mimic the natural function of proteins and peptides in the body.
Weakness: Short biological half-life requiring frequent dosing. High production costs and complexity in manufacturing.
Opportunity: Wide scope for developing novel peptide drugs for various therapeutic areas. Growing focus on protein and peptide-based drugs for both chronic and rare diseases.
Threats: Stiff competition from conventional small molecule drugs and biologics. Stringent regulatory requirements and clinical trial data requirements.
Geographically, North America accounts for the largest share of peptide therapeutics market, primarily driven by extensive R&D investments and presence of major players in the US. Europe also represents a major market due to growing biotech industry and increasing focus on development of personalized medicines. Asia Pacific is fastest growing regional market for peptide therapeutics driven by expanding healthcare infrastructure, rising medical expenditures, and growing acceptance of novel drugs. China and India offer lucrative opportunities for market players due to rising affluence, large patient pool and increasing focus on specialty medicines.
In terms of value, the US market currently holds the largest share in global peptide therapeutics market due to advanced research capabilities, availability of funding and presence of major pharmaceutical companies. However, China is emerging as the fastest growing regional market expected to surpass major Western markets by late 2020s owing to rising medical requirements of large population, improving research ecosystem and favorable regulatory guidelines to promote innovation.